郑州微飒生物科技有限责任公司 咨询热线:0371-88821766
行业动态

行业动态

追踪行业前沿,洞察产业趋势

药效评价Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy.

期刊:British journal of pharmacology发表年份:2011作者:J Jakubík; H Janíčková; E E El-Fakahany; V Doležal

药效评价Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

期刊:Antimicrobial agents and chemotherapy发表年份:2011作者:Antara Banerjee; Manjarika De; Nahid Ali

药效评价Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.

期刊:British journal of pharmacology发表年份:2011作者:Simeon J Ramsey; Neil J Attkins; Rebecca Fish; Piet H van der Graaf

药效评价The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

期刊:Movement disorders : official journal of the Movement Disorder Society发表年份:2011作者:James B Koprich; Susan H Fox; Tom H Johnston; Allan Goodman; Bertrand Le Bourdonnec; Roland E Dolle; Robert N DeHaven; Diane L DeHaven-Hudkins; Patrick J Little; Jonathan M Brotchie